The drug for treatment of dandruff :: Consumers survey results of for 1 quarter of 2024

Consumers survey results of for 1 quarter of 2024 in category

Dermatology, means for external use / The drug for treatment of dandruff

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	I quarter (january—march)
	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.	Сульсена (Амальгама Люкс)	75.00%	5

2.	Дермазол (Kusum Pharm)	50.00%	3.33

3.	Кеназол (Pharma International)	25.00%	1.67

3.	Кето Плюс (Glenmark Farmaceuticals Limited)	25.00%	1.67

–.	Algopix (СЕБ-Фармація)	0.00%	0

–.	Ebersept (PharmUnion)	0.00%	0

–.	Nizoral (Janssen)	0.00%	0

–.	Sebiprox (Stiefel Laboratories Inc)	0.00%	0

–.	TerbinaКод (ФітоБіоТехнології)	0.00%	0

–.	Кетозорал (Darnitsa)	0.00%	0

–.	Ламікон (Farmak)	0.00%	0

This rating reflects the current interim results of the study of public opinion as on 11/24/2024 22:13:21 and it’s not yet final.

Strictly prohibited any use and reproduction of unfinished voting results without link to the source, without clear explanation of the methodology of the “Favorites of Success” Contest and without mandatory notes that poll is still continues and this result is not yet final.